Bare-metal Stents Market to Achieve Remarkable Growth, Projected at 5.2% CAGR, and Surpassing USD 4.8 Billion by 2031 – TMR Study
May 24, 2023 04:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, May 24, 2023 (GLOBE NEWSWIRE) -- The global bare metal stents market is projected to flourish at a CAGR of 5.2% from 2023 to 2031. As per the report published by...
New Assessment Scale to Measure Adherence to Oral Anticoagulants Based on Impact of Patient Relevant Bleeding in Atrial Fibrillation Presented at ISPOR 2023
May 09, 2023 09:45 ET
|
Anthos Therapeutics
Anticoagulant Bleeding Burden Adherence Confidence Assessment Scale [ABBA-CAS] Created to Better Address an Important Treatment Gap in the Management of Atrial Fibrillation (AF) and Bring Patient...
New Assessment Scale to Capture Patient Relevant Bleeding to be Presented at ISPOR 2023
May 05, 2023 08:00 ET
|
Anthos Therapeutics
Additional presentation spotlights GARDENIA registry design in patientswith atrial fibrillation and atrial flutter Early Cost-Effectiveness Modeling for Patients with Atrial Fibrillation and Cancer...
Aronora CEO Named National Academy of Inventors Fellow
December 08, 2022 10:00 ET
|
Aronora, Inc
PORTLAND, Ore., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Erik Tucker, Ph.D., joins an elite group of inventors with his election to the National Academy of Inventors. Dr. Tucker's research into blood...
Aronora Announces Clinical Data to Be Presented at the 64th American Society of Hematology Annual Meeting
December 06, 2022 07:00 ET
|
Aronora, Inc
PORTLAND, Ore., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Aronora Inc., a clinical-stage biotechnology company developing next-generation therapeutics for blood clotting diseases, announced today that...
United States Deep Vein Thrombosis Interventions Landscape Report 2022: Focus on Interventional Radiologists and Vascular Surgeons
October 13, 2022 04:28 ET
|
Research and Markets
Dublin, Oct. 13, 2022 (GLOBE NEWSWIRE) -- The "The United States Deep Vein Thrombosis Interventions Landscape, Procedure and Technology Trends, Brand Perception, Competitive Intelligence and Future...
Anthos Therapeutics Launches Second Phase 3 Clinical Trial of Its Dual-acting Factor XI Inhibitor, Abelacimab
August 25, 2022 08:00 ET
|
Anthos Therapeutics
Abelacimab is the only Factor XI inhibitor currently being evaluated in Phase 3 trials The MAGNOLIA study will compare abelacimab against the current standard of care for VTE in cancer associated...
Worldwide Varicose Vein Treatments Industry to 2026 - Impact of Demographic, Economic, and Other Factors That Will Drive Future Demand
May 14, 2021 05:03 ET
|
Research and Markets
Dublin, May 14, 2021 (GLOBE NEWSWIRE) -- The "Global Varicose Vein Treatments Market 2021-2026" report has been added to ResearchAndMarkets.com's offering. Varicose veins treatment includes...
Amaranth Medical Completes MEND-II and RENASCENT Studies and Initiates Study of 120-Micron APTITUDE Sirolimus-Eluting Bioresorbable Scaffold
October 15, 2015 08:00 ET
|
Amaranth Medical, Inc.
MOUNTAIN VIEW, CA, Oct. 15, 2015 (GLOBE NEWSWIRE) -- Amaranth Medical, a privately held medical device company, announced that enrollment has successfully concluded in its multi-center, international...
Amaranth Medical Reports Positive Safety and Feasibility Findings for the FORTITUDE(TM) Bioresorbable Scaffold
October 28, 2013 08:00 ET
|
Amaranth Medical, Inc.
MOUNTAIN VIEW, CA, Oct. 28, 2013 (GLOBE NEWSWIRE) -- Amaranth Medical, a privately held medical device company,
presented positive six-month angiographic results from its
first-in-human study...